<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005652</url>
  </required_header>
  <id_info>
    <org_study_id>199/15038</org_study_id>
    <secondary_id>UAB-9866</secondary_id>
    <secondary_id>UAB-BB-IND-8136</secondary_id>
    <secondary_id>UAB-F990224001</secondary_id>
    <nct_id>NCT00005652</nct_id>
  </id_info>
  <brief_title>Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients&#xD;
      with immune thrombocytopenic purpura.&#xD;
&#xD;
      II. Evaluate the toxicity associated with this treatment regimen in these patients.&#xD;
&#xD;
      III. Evaluate the alteration in antiplatelet antibody with this treatment regimen in these&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients receive rituximab IV on days 1, 8, 15, and 22. Patients who&#xD;
      achieve a clinical response lasting over 4 months may receive a second course of rituximab.&#xD;
&#xD;
      Patients are followed at 5, 6, 8, and 12 weeks, and then at 6 and 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>Purpura, Thrombocytopenic, Idiopathic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Clinically confirmed immune thrombocytopenic purpura (ITP) Platelet count less than&#xD;
        75,000/mm3 on two occasions at least 1 week apart within past month&#xD;
&#xD;
        Normal to increased numbers of megakaryocytes on bone marrow examination within past 6&#xD;
        months&#xD;
&#xD;
        Failed prior steroid therapy (i.e., unable to achieve sustained platelet count greater than&#xD;
        75,000/mm3)&#xD;
&#xD;
        No drug associated ITP&#xD;
&#xD;
        No B cell malignancies&#xD;
&#xD;
        No evidence of disseminated intravascular coagulation (DIC)&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        Endocrine therapy: Concurrent steroids allowed as long as platelet count is less than&#xD;
        75,000/mm3 and dose is not changed within past 2 weeks or during study&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent medical therapy for immune thrombocytopenia purpura (ITP)&#xD;
&#xD;
          -  At least 2 weeks since prior therapy for ITP (except steroids)&#xD;
&#xD;
          -  At least 4 weeks since prior cyclosporine&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Performance status: ECOG 0-2&#xD;
&#xD;
        Life expectancy: At least 6 months&#xD;
&#xD;
        Renal: Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular: No congestive heart failure or symptomatic coronary insufficiency&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No clinically significant bleeding (i.e., other than mild mucosal bleeding or&#xD;
             petechiae)&#xD;
&#xD;
          -  No sepsis or fever&#xD;
&#xD;
          -  No active infection requiring therapy&#xD;
&#xD;
          -  No active chronic viral infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other concurrent or prior malignancy within past 5 years except squamous or basal&#xD;
             cell carcinoma of the skin or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mansoor Noorali Saleh</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>May 2, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2000</study_first_posted>
  <last_update_submitted>September 8, 2008</last_update_submitted>
  <last_update_submitted_qc>September 8, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2008</last_update_posted>
  <keyword>hematologic disorders</keyword>
  <keyword>immune thrombocytopenic purpura</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

